OncoBreak: Brilliance vs Compassion; Third-Hand Smoke; Trusted Pharma
(MedPage Today) -- News, features, and commentary about cancer-related issues (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 10, 2018 Category: American Health Source Type: news

How this biotech nearly tripled its IPO price with a buyout in less than 4 months
Pharma giant Eli Lilly and Co. will buy small cancer immunotherapy drug developer ARMO BioSciences Inc., a Redwood City company that went public in January, in a $1.6 billion all-cash deal. Lilly's $50-per-share buyout is nearly three times ARMO's (NASDAQ: ARMO) $17-per-share initial public offering price, offering a relatively quick return for investors, including venture capital firms Kleiner Perkins Caufield& Byers and OrbiMed Advisors, whose public shares still were under customary IPO lockups. … (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 10, 2018 Category: American Health Authors: Ron Leuty Source Type: news

Lilly Announces Agreement To Acquire ARMO BioSciences
$1.6 billion transaction will bolster Lilly's clinical portfolio with ARMO's lead immuno-oncology asset, pegilodecakin, which is being studied in multiple tumor types INDIANAPOLIS and REDWOOD CITY, Calif., May 10, 2018 -- (Healthcare Sales & Marketing N... Biopharmaceuticals, Oncology, Mergers & Acquisitions Eli Lilly, ARMO BioSciences, pegilodecakin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 10, 2018 Category: Pharmaceuticals Source Type: news

New cancer immunotherapy drugs rapidly reach patients after approval
The majority of patients eligible for cancer drugs known as checkpoint inhibitors received treatment within months of FDA approval, according to a new study. (Source: Yale Science and Health News)
Source: Yale Science and Health News - May 10, 2018 Category: Universities & Medical Training Source Type: news

Scientists Identify Why Some People May Be Resistant To PARP Inhibitor Drugs
Researchers identify why some women may be resistant to brand new FDA-approved drug for breast and ovarian cancer. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 10, 2018 Category: Pharmaceuticals Authors: Victoria Forster, Contributor Source Type: news

Lilly to buy Armo Biosciences for $1.6 billion to bolster cancer pipeline
(Reuters) - Eli Lilly and Co said on Thursday it would buy Armo BioSciences Inc for about $1.6 billion to expand its portfolio of drugs that seeks to help body's immune system fight cancer as the drugmaker chases its rivals in a lucrative market. (Source: Reuters: Health)
Source: Reuters: Health - May 10, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Pancreatic cancer breakthrough: New treatment hope for fifth biggest cancer killer in UK
PANCREATIC cancer symptoms include stomach pain, weight loss and nausea or vomiting. It affects the pancreas, which produces the hormone insulin that regulates blood sugar levels. The fifth biggest cancer in the UK, scientists have just discovered a way to slow the condition. (Source: Daily Express - Health)
Source: Daily Express - Health - May 10, 2018 Category: Consumer Health News Source Type: news

Peritoneal Mesothelioma Specialist Takes Expertise to South Florida
Dr. Shanel Bhagwandin saw the steady flow of patients who traveled from Southeast Florida to New York’s renowned Mount Sinai Hospital for the specialized treatment of peritoneal mesothelioma cancer. He knew there was a better way, and he just made it happen. Bhagwandin made the 1,200-mile move himself — from Mount Sinai to the Jupiter Medical Center — to start the latest surgical oncology program that specializes in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). “This procedure can make a tremendous difference,” Bhagwandin told Asbestos.com. “And it makes a ...
Source: Asbestos and Mesothelioma News - May 10, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Cancer delays 'leave patients at risk'
UK struggling to hit cancer targets as number of cancelled operations hit record high in England. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - May 10, 2018 Category: Consumer Health News Source Type: news

Leukemia: Five easily overlooked signs you have the condition
LEUKEMIA, or blood cancer, symptoms are not always easily detected. The condition has several forms including acute myeloid leukaemia and chronic leukemia. You should look out for these five symptoms of the condition. (Source: Daily Express - Health)
Source: Daily Express - Health - May 10, 2018 Category: Consumer Health News Source Type: news

Nodal Metastasis Risk Up When Cancer Is Directly on the Lip
THURSDAY, May 10, 2018 -- The risk of nodal metastasis is five-fold greater for skin cancer on the vermilion lip versus the cutaneous lip, according to a study published online May 2 in JAMA Dermatology. David M. Wang, from Case Western Reserve... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 10, 2018 Category: Pharmaceuticals Source Type: news

Improved survival rates linked to cancer treatment-induced hypothyroidism
Hypothyroidism caused by tyrosine kinase inhibitors used in thyroid cancer treatment has been linked to longer survival rates, according to a study published inThyroid.Medscape (Source: Society for Endocrinology)
Source: Society for Endocrinology - May 10, 2018 Category: Endocrinology Source Type: news

Triad cancer center to change its name, offer more services
The former Smith McMichael Cancer Center in Eden will open on May 15 with a new name and services. UNC Health Care, which took ownership of the center this year, is renaming the clinic UNC Cancer Care at Rockingham, while also adding medical oncology and infusion services to the facility's offerings. The center will operate as a service of UNC Hospitals. UNC Cancer Care will increase its work force from 10 employees to 18 people when it adds the new services. The clinic only offered radiation… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - May 10, 2018 Category: Health Management Authors: Jessica Seaman Source Type: news

Triad cancer center to change its name, offer more services
The former Smith McMichael Cancer Center in Eden will open on May 15 with a new name and services. UNC Health Care, which took ownership of the center this year, is renaming the clinic UNC Cancer Care at Rockingham, while also adding medical oncology and infusion services to the facility's offerings. The center will operate as a service of UNC Hospitals. UNC Cancer Care will increase its work force from 10 employees to 18 people when it adds the new services. The clinic only offered radiation… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 10, 2018 Category: Biotechnology Authors: Jessica Seaman Source Type: news

Setback to Roche hopes for Tecentriq as fails key cancer trial
ZURICH (Reuters) - Roche's hopes of its Tecentriq immunotherapy catching up rival medicines from Merck and Bristol-Myers Squibb were dealt a blow on Thursday after it failed a key combination trial. (Source: Reuters: Health)
Source: Reuters: Health - May 10, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Better cancer diagnostic tests in sight as scientists discover a previously unknown organ in our body
(Natural News) For decades, scientists have thought that they had discovered all of the human body’s organs and focused their research on them. But a new study by New York University (NYU) pathologists found that this is not so. They discovered a new organ, which they had missed using standard ways of examining the body’s complex internal system. The new organ is called the interstitium. It... (Source: NaturalNews.com)
Source: NaturalNews.com - May 10, 2018 Category: Consumer Health News Source Type: news

Zimbabwe:Breast Cancer Victim Seeks Help
[The Herald] A Harare woman who was diagnosed with breast cancer is appealing for financial assistance to buy medication. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - May 10, 2018 Category: African Health Source Type: news

Osimertinib Improves Patient-Reported Outcomes in Advanced NSCLC
An analysis of patient-reported outcomes showed that osimertinib yielded a longer time to deterioration compared with chemotherapy in patients with advanced non –small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 10, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer SiteTerms/www.cannabissciencetech.com/News Source Type: news

Uganda:Second Cancer Machine Arrives in August
[Observer] A second Cobalt 60 radiotherapy machine will be delivered to Mulago national referral hospital in August, installed in September and by December, cancer patients will start using it, Uganda Cancer Institute (UCI) has announced. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - May 10, 2018 Category: African Health Source Type: news

Health Tip: Manage Your Daily Medication
-- It may be no small chore to manage all of the prescription drugs, over-the-counter meds and supplements you're taking. The American Cancer Society offers these suggestions: Create a chart of your daily medication schedule and use it to remind... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 10, 2018 Category: General Medicine Source Type: news

Medical News Today: Body clock gene may protect against breast cancer
One of the genes that regulate our circadian rhythm might also contribute to the normal development of mammary glands and protect against breast cancer. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 10, 2018 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Nigeria:10 Nigerians Die From Cancer Every Hour, Says Expert
[This Day] At least 10 Nigerians die from cancer every hour in Nigeria, while at least 80,000 cases are diagnosed in the country every year, experts have said. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - May 10, 2018 Category: African Health Source Type: news

Perioperative VTE in Urologic Oncology Procedures Perioperative VTE in Urologic Oncology Procedures
Learn more about the risk for venous thromboembolism among patients undergoing major urologic oncology operations, and find out how best to prevent this complication.Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 10, 2018 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer
Roche today announced that the Phase III IMblaze370 study evaluating the combination of Tecentriq ® (atezolizumab) and Cotellic® (cobimetinib) did not meet its primary endpoint of overall survival (OS) compared to regorafenib. The study evaluated the combination in people with difficult-to-treat, locally advanced or metastatic colorectal cancer (CRC) whose disease progressed or who were intole rant to at least two systemic chemotherapy regimens. (Source: Roche Media News)
Source: Roche Media News - May 10, 2018 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer
Roche today announced that the Phase III IMblaze370 study evaluating the combination of Tecentriq ® (atezolizumab) and Cotellic® (cobimetinib) did not meet its primary endpoint of overall survival (OS) compared to regorafenib. The study evaluated the combination in people with difficult-to-treat, locally advanced or metastatic colorectal cancer (CRC) whose disease progressed or who were intole rant to at least two systemic chemotherapy regimens. (Source: Roche Investor Update)
Source: Roche Investor Update - May 10, 2018 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer
Roche today announced that the Phase III IMblaze370 study evaluating the combination of Tecentriq ® (atezolizumab) and Cotellic® (cobimetinib) did not meet its primary endpoint of overall survival (OS) compared to regorafenib. The study evaluated the combination in people with difficult-to-treat, locally advanced or metastatic colorectal cancer (CRC) whose disease progressed or who were intole rant to at least two systemic chemotherapy regimens. (Source: Roche Media News)
Source: Roche Media News - May 10, 2018 Category: Pharmaceuticals Source Type: news

Study reveals that many oncologists recommend medical marijuana clinically despite not feeling sufficiently knowledgeable to do so
(Dana-Farber Cancer Institute) While a wide majority of oncologists do not feel informed enough about medical marijuana's utility to make clinical recommendations, most do in fact conduct discussions on medical marijuana in the clinic and nearly half recommend it to their patients, say researchers who surveyed a population-based sample of medical oncologists. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 10, 2018 Category: Cancer & Oncology Source Type: news

Racial-ethnic disparities in the quality of end-of-life care among lung cancer patients
(International Association for the Study of Lung Cancer) Significant disparities in the quality of end-of-life lung cancer care were found among racial-ethnic minorities, with higher odds of experiencing potentially preventable medical encounters during end-of-life as compared with non-Hispanic whites. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 10, 2018 Category: International Medicine & Public Health Source Type: news

Most oncologists have discussed medical marijuana with patients
(American Society of Clinical Oncology) Data from a new survey show that as many as 80 percent of oncologists have discussed medical marijuana use with their patients. According to the authors, this is the first nationally-representative survey to examine oncologists' practices and beliefs on the subject since the implementation of state medical marijuana laws. The research published online today in the Journal of Clinical Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 10, 2018 Category: International Medicine & Public Health Source Type: news

New cancer immunotherapy drugs rapidly reach patients after approval
(Yale University) The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study. The finding suggests that cancer immunotherapies are adopted at a much quicker pace than is typical for newly approved medical treatments, the researchers said. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 10, 2018 Category: Cancer & Oncology Source Type: news

Shooting the Achilles heel of drug-resistant cancer
(Netherlands Cancer Institute) Cancer cells that develop resistance to drugs, also develop a new vulnerability. If this can be identified, it may be exploited clinically. A team of cancer researchers, led by Rene Bernards of the Netherlands Cancer Institute and Oncode Institute, now exposed this acquired vulnerability in melanoma that has developed resistance to treatment with BRAF-inhibitors. The team then developed a new therapeutic strategy to selectively kill the drug-resistant cancer cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 10, 2018 Category: Cancer & Oncology Source Type: news

Depleted metabolic enzymes promote tumor growth in kidney cancer
(University of Pennsylvania School of Medicine) By integrating data on the function of essential metabolic enzymes with genetic, protein, and metabolic abnormalities associated with " clear cell " renal cell carcinoma (ccRCC), researchers have determined that enzymes important in multiple pathways are universally depleted in ccRCC tumors. Kidney cancer, one of the ten most prevalent malignancies in the world, has increased in incidence over the last decade, likely due to rising obesity rates. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 10, 2018 Category: Cancer & Oncology Source Type: news

Boosting the effects of vitamin D to tackle diabetes
(Salk Institute) A Salk Institute study suggests new approach for treating type 2 diabetes and other diseases, including cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 10, 2018 Category: Cancer & Oncology Source Type: news

Pterocarpanquinones and carbapterocarpans with anti-tumor activity against MDR leukemias
(Bentham Science Publishers) The pterocarpanquinone LQB-118 and the carbapterocarpan LQB-223 were evaluated on models of human hematological neoplasias and solid tumors. Both compounds presented great selectivity and anti-MDR capabilities, seeming to 'adapt' their mode of action to circumvent diverse phenotypes of drug resistance, especially on leukemic cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 10, 2018 Category: Cancer & Oncology Source Type: news

Study paves the way for better treatment of prostate cancer
(University of Manchester) A new study published today has found a way to identify men with locally advanced prostate cancer who are less likely to respond well to radiotherapy.Led by Professor Catharine West, the University of Manchester team created a method of selecting prostate cancer patients who would benefit from treatments which target oxygen deficient tumors.The study was funded by Prostate Cancer UK and NIHR Manchester Biomedical Research Centre and published in eBiomedicine today. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 10, 2018 Category: Cancer & Oncology Source Type: news

Scientists identify cause of resistance to breakthrough breast and ovarian cancer drug
(Institute of Cancer Research) Findings could allow doctors to predict resistance and lead to changes in treatment. New gene editing technique used to unearth mutation linked to resistance to targeted PARP inhibitor treatments. Scientists have identified a mutation that gives cancer cells resistance to the breakthrough cancer treatment olaparib and other PARP inhibitors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 10, 2018 Category: International Medicine & Public Health Source Type: news

Living with cancer: how going back to work can help
Many people say office life supports a return to normality — and employers can assist (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 10, 2018 Category: Pharmaceuticals Source Type: news

Cochrane Review Backs HPV Vax For Girls, Young Women
(MedPage Today) -- Lower risk of cervical lesions in those who received vaccine versus placebo (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 10, 2018 Category: Hematology Source Type: news

Society for Immunotherapy of Cancer (SITC)-Led Study Demonstrating...
An international consortium led by the Society for Immunotherapy of Cancer (SITC) has published the results of a ground-breaking study that demonstrates the immune system’s important role in colon...(PRWeb May 10, 2018)Read the full story at http://www.prweb.com/releases/2018/05/prweb15479857.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 10, 2018 Category: Pharmaceuticals Source Type: news

A new cancer immunotherapy suffers a setback
(Source: ScienceNOW)
Source: ScienceNOW - May 10, 2018 Category: Science Authors: Garber, K. Tags: Cell Biology, Medicine, Diseases In Depth Source Type: news

Lymphoma, Leukemia Survivors Have Increased Health Care Use
Survivors who are psychologically distressed use even more services than those who aren't (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - May 10, 2018 Category: Psychiatry Tags: Family Medicine, Geriatrics, Internal Medicine, Nursing, Oncology, Psychiatry, Journal, Source Type: news

USPSTF Issues New Recommendation On Prostate Cancer Screening
BOSTON (CBS) — A leading task force has come out with new recommendations when it comes to prostate cancer screening in men. The U.S. Preventative Services Task Force (USPSTF) now recommends that men between the ages of 55 and 69 without symptoms be offered a PSA test if they have been educated on the pros and cons of testing. The USPSTF also recommends against PSA screening in men aged 70 and older. The PSA test is a simple blood test that attempts to identify men at risk of prostate cancer, but false-positive results can lead to over-diagnosis and unwanted side effects like incontinence and erectile dysfunction. Re...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 9, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Healthwatch Seen On WBZ-TV Syndicated Local Cancer Screening Dr. Mallika Marshall Local TV Prostate Cancer Source Type: news

An important message to our patients
(Source: Karmanos Cancer Institute)
Source: Karmanos Cancer Institute - May 9, 2018 Category: Cancer & Oncology Source Type: news

Intravesical Gemcitabine Reduces Bladder Ca Recurrence
(MedPage Today) -- Could be more feasible than mitomycin C (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 9, 2018 Category: Hematology Source Type: news

Matter: In Ancient Skeletons, Scientists Discover a Modern Foe: Hepatitis B
From 15 sets of skeletal remains, researchers have recovered DNA from the oldest viruses known to have infected humans — and have resurrected some strains in the laboratory. (Source: NYT Health)
Source: NYT Health - May 9, 2018 Category: Consumer Health News Authors: CARL ZIMMER Tags: Hepatitis Genetics and Heredity Skeletons Viruses Bones Bronze Age Liver Cancer Epidemics Cambridge University Nature (Journal) University of Copenhagen eLife (Journal) Source Type: news

Check-Cap closes $20m Series C
Check-Cap (NSDQ:CHEK) said yesterday it closed an offering of Series C shares and warrants, raising approximately $20.2 million in total. In the offering, the Isfiya, Israel-based company floated approximately 3.2 million units for $5.50 per unit, with each unit in the offering consisting of a single ordinary share or ordinary share equivalent and a Series C warrant to purchase one ordinary share. The offering also included an underwriter’s option for an additional 478,407 shares and Series C warrants to purchase up to 478,407 shares, which was exercised in full, Check-Cap said. Proceeds from the round are slate...
Source: Mass Device - May 9, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Funding Roundup Wall Street Beat Check-Cap Source Type: news

Non-AIDS Cancers Expected to Dominate in HIV-infected Adults by 2030 Non-AIDS Cancers Expected to Dominate in HIV-infected Adults by 2030
Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 9, 2018 Category: Infectious Diseases Tags: Hematology-Oncology News Source Type: news

Bioimpedance Spectroscopy Spots Breast Cancer-related Lymphedema Early Bioimpedance Spectroscopy Spots Breast Cancer-related Lymphedema Early
Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - May 9, 2018 Category: Surgery Tags: Hematology-Oncology News Source Type: news

California Judge Finalizes Ruling on Coffee Cancer Warnings California Judge Finalizes Ruling on Coffee Cancer Warnings
A Los Angeles judge has finalized a ruling that Starbucks Corp and other coffee sellers must serve up a cancer warning with coffee sold in California.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 9, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Patient and Tumor Features Predicted RCC Outcomes Post Nephrectomy
Routinely available patient and tumor features accurately predicted the risk progression and death from RCC post nephrectomy, a Mayo Clinic team found. (Source: CancerNetwork)
Source: CancerNetwork - May 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news